Nutrition Research and Practice

The Korean Nutrition Society (한국영양학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of retinoic acid and delta-like 1 homologue (DLK1) on differentiation in neuroblastoma

  • Kim, Yu-Ri (Department of Nutritional Science and Food Management, Ewha Womans University)
  • Received : 2010.05.17
  • Accepted : 2010.07.05
  • Published : 2010.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

The principal objective of this study was to evaluate the chemopreventive and therapeutic effects of a combination of all-trans-retinoic acid (RA) and knockdown of delta-like 1 homologue (Drosophila) (DLK1) on neuroblastoma, the most common malignant disease in children. As unfavorable neuroblastoma is poorly differentiated, neuroblastoma cell was induced differentiation by RA or DLK1 knockdown. Neuroblastoma cells showed elongated neurite growth, a hallmark of neuronal differentiation at various doses of RA, as well as by DLK1 knockdown. In order to determine whether or not a combination of RA and DLK1 knockdown exerts a greater chemotherapeutic effect on neuroblastoma, cells were incubated at 10 nM RA after being transfected with SiRNA-DLK1. Neuronal differentiation was increased more by a combination of RA and DLK1 knockdown than by single treatment. Additionally, in order to assess the signal pathway of neuroblastoma differentiation induced by RA and DLK1 knockdown, treatment with the specific MEK/ERK inhibitors, U0126 and PD 98059, was applied to differentiated neuroblastoma cells. Differentiation induced by RA and DLK1 knockdown increased ERK phosphorylation. The MEK/ERK inhibitor U0126 completely inhibited neuronal differentiation induced by both RA and DLK1 knockdown, whereas PD98059 partially blocked neuronal differentiation. After the withdrawal of inhibitors, cellular differentiation was fully recovered. This study is, to the best of our knowledge, the first to demonstrate that the specific inhibitors of the MEK/ERK pathway, U0126 and PD98059, exert differential effects on the ERK phosphorylation induced by RA or DLK1 knockdown. Based on the observations of this study, it can be concluded that a combination of RA and DLK1 knockdown increases neuronal differentiation for the control of the malignant growth of human neuroblastomas, and also that both MEK1 and MEK2 are required for the differentiation induced by RA and DLK1 knockdown.

Keywords

References

  1. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
  2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16. https://doi.org/10.1038/nrc1014
  3. Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004;45: 1172-88.
  4. De Preter K, Vandesompele J, Heimann P, Beckman S, Schramm A, Eggert A, Stallings RL, Benoit Y, Renard M, De Paepe A, Laureys G, Piahlman S, Speleman F. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 2006;7:R84. https://doi.org/10.1186/gb-2006-7-9-r84
  5. Vasudevan SA, Nuchtem JG, Shohet JM. Gene profiling of high risk neuroblastoma. World J Surg 2005;29:317-24. https://doi.org/10.1007/s00268-004-7820-7
  6. Matthay KK, Haas-Kogan D, Constine LS. Neuroblastoma. In: Halperin, EC, Constine LS, Tarbell NJ, Kun LE, editors. Pediatric Radiation Oncology. Philadelphia: Lippincott Williams & Wilkins; 2005. p.179-222.
  7. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D; European Neuroblastoma Study Group; Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group). High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008;9: 247-56. https://doi.org/10.1016/S1470-2045(08)70069-X
  8. Smith MA, Anderson B. Where to next with retinoids for cancer therapy? Clin Cancer Res 2001;7:2955-7.
  9. Goodman DS, Huang HS. Biosynthesis of vitamin a with rat intestinal enzymes. Science 1965;149:879-80. https://doi.org/10.1126/science.149.3686.879
  10. von Lintig J, Vogt K. Filling the gap in vitamin A research. Molecular identification of an enzyme cleaving beta-carotene to retinal. J Biol Chem 2000;275:11915-20. https://doi.org/10.1074/jbc.275.16.11915
  11. Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol 2006;66:606-30. https://doi.org/10.1002/neu.20242
  12. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux, N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94: 1192-200.
  13. Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, Sanz M, Link H, Maloisel F, Gardin C, Bordessoule D, Stoppa AM, Sadoun A, Muus P, Wandt H, Mineur P, Whittaker JA, Fey M, Daniel MT, Castaigne S, Degos L. Long-term followup confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000; 14:1371-7. https://doi.org/10.1038/sj.leu.2401859
  14. Laborda J. The role of the epidermal growth factor-like protein dlk in cell differentiation. Histol Histopathol 2000;15:119-29.
  15. Floridon C, Jensen CH, Thorsen P, Nielsen O, Sunde L, Westergaard JG, Thomsen SG, Teisner B. Does fetal antigen 1(FA1) identify cells with regenerative, endocrine and neuroendocrine potentials? A study of FA1 in embryonic, fetal, and placental tissue and in maternal circulation. Differentiation 2000;66:49-59. https://doi.org/10.1046/j.1432-0436.2000.066001049.x
  16. Smas CM, Sui HS. Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 1993;73:725-34. https://doi.org/10.1016/0092-8674(93)90252-L
  17. Tomehave D, Jensen CH, Teisner B, Larsson LI. FAI immunoreactivity in endocrine tumours and during development of the human fetal pancreas; negative correlation with glucagon expression. Histochem Cell Biol 1996;106:535-42. https://doi.org/10.1007/BF02473268
  18. Villena JA, Kim KH, Sul HS. Pref-1 and ADSF/resistin: two secreted factors inhibiting adipose tissue development. Horm Metab Res 2002;34:664-70. https://doi.org/10.1055/s-2002-38244
  19. Li L, Forman SJ, Bhatia R. Expression of DLK1 in hematopoietic cells results in inhibition of differentiation and proliferation. Oncogene 2005;24:4472-6. https://doi.org/10.1038/sj.onc.1208637
  20. Sakajiri S, O'Kelly J, Yin D, Miller CW, Hofmann WK, Oshimi K, Shih L Y, Kim KH, Sul HS, Jensen CH, Teisner B, Kawamata N, Koeffier HP. Dlkl in normal and abnormal hematopoiesis. Leukemia 2005;19:1404-10. https://doi.org/10.1038/sj.leu.2403832
  21. Bauer SR, Ruiz-Hidalgo MJ, Rudikoff EK, Goldstein J, Laborda J. Modulated expression of the epidermal growth factor-like homeotic protein dlk influences stromal-cell-pre-B-cell interactions, stromal cell adipogenesis, and pre-B-cell interleukin-7 requirements. Mol Cell Biol 1998;18:5247-55.
  22. Kaneta M, Osawa M, Sudo K, Nakauchi H, Farr AG, Takahama Y. A role for pref-1 and HES-1 in thymocyte development. J Immunol 2000; 164:256-64.
  23. Van Limpt VA, Chan AJ, Van Sluis PG, Caron HN, Van Noesel CJ, Versteeg R. High delta-like 1 expression in a subset of neuroblastoma cell lines corresponds to a differentiated chromaffin cell type. Int J Cancer 2003;105:61-9. https://doi.org/10.1002/ijc.11047
  24. Laborda J, Sausville EA, Hoffman T, Notario V. dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line. J Biol Chem 1993;268:3817-20.
  25. Yin D, Xie D, Sakajiri S, Miller CW, Zhu H, Popoviciu ML, Said JW, Black KL. Koeffler HP. DLKI: increased expression in gliomas and associated with oncogenic activities. Oncogene 2006;25: 1852-61. https://doi.org/10.1038/sj.onc.1209219
  26. Kim Y, Lin Q, Zelterman D, Yun Z. Hypoxia-regulated delta-like 1 homologue enhances cancer cell sternness and tumorigenicity. Cancer Res 2009;69:9271-80. https://doi.org/10.1158/0008-5472.CAN-09-1605
  27. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 1995;80:225-36. https://doi.org/10.1016/0092-8674(95)90405-0
  28. Berwick DC, Calissano M, Comess JD, Cook SJ, Latchman DS. Regulation of Bm-3a N-terminal transcriptional activity by MEK1/2-ERK1/2 signalling in neural differentiation. Brain Res 2009;1256:8-18. https://doi.org/10.1016/j.brainres.2008.12.009
  29. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogenactivated protein kinase kinase in vitro and in vivo. J BioI Chem 1995;270:27489-94. https://doi.org/10.1074/jbc.270.46.27489
  30. Cuenda A, Alessi DR. Use of kinase inhibitors to dissect signaling pathways. Methods Mol Biol 2000;99:161-75.
  31. Ahn NG, Nahreini TS, Tolwinski NS, Resing KA. Pharmacologic inhibitors of MKK1 and MKK2. Methods Enzymol 2001;332: 417-31. https://doi.org/10.1016/S0076-6879(01)32219-X
  32. Yun Z, Lin Q, Giaccia AJ. Adaptive myogenesis under hypoxia. Mol Cell Biol 2005;25:3040-55. https://doi.org/10.1128/MCB.25.8.3040-3055.2005
  33. Katayama K, Wada K, Miyoshi H, Ohashi K, Tachibana M, Furuki R, Mizuguchi H, Hayakawa T, Nakajima A, Kadowaki T, Tsutsumi Y, Nakagawa S, Kamisaki Y, Mayumi T. RNA interfering approach for clarifying the PPARgamma pathway using lentiviral vector expressing short hairpin RNA. FEBS Lett 2004;560: 178-82. https://doi.org/10.1016/S0014-5793(04)00100-0
  34. De los Santos M, Zambrano A, Aranda A. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther 2007;6:1425-32. https://doi.org/10.1158/1535-7163.MCT-06-0623
  35. Natale RB. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2008;3:S128-30. https://doi.org/10.1097/JTO.0b013e318174e95a
  36. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewen GR, Truglia JA, Warrell RP, Jr. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997;15:790-5.
  37. Shalinsky DR, Bischoff ED, Gregory ML, Lamph WW, Heyman RA, Hayes JS. Thomazy V, Davies PJ. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin Cancer Res 1996;2:511-20.
  38. Laborda J. The role of the epidermal growth factor-like protein dlk in cell differentiation. Histol Histopathol 2000;15:119-29.
  39. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105. https://doi.org/10.1042/0264-6021:3510095
  40. Favata MF, Horiuchi KY, Manos EJ, Daulerio, AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-32. https://doi.org/10.1074/jbc.273.29.18623
  41. Dang ZC, Lowik CW. Differential effects of PD98059 and U0l26 on osteogenesis and adipogenesis. J Cell Biochem 2004; 92:525-33. https://doi.org/10.1002/jcb.20087

Cited by

  1. Mulberry Leaf Extract Inhibits Cancer Cell Stemness in Neuroblastoma vol.64, pp.6, 2012, https://doi.org/10.1080/01635581.2012.707280
  2. Effect of β-carotene on cancer cell stemness and differentiation in SK-N-BE(2)C neuroblastoma cells vol.30, pp.4, 2013, https://doi.org/10.3892/or.2013.2643
  3. Molecular mechanisms of dopaminergic subset specification: fundamental aspects and clinical perspectives vol.71, pp.24, 2014, https://doi.org/10.1007/s00018-014-1681-5
  4. Paired Expression Analysis of Tumor Cell Surface Antigens vol.7, pp.2234-943X, 2017, https://doi.org/10.3389/fonc.2017.00173
  5. Effect of DLK1 on tumorigenesis in CD34+CD38− bone marrow cells in myelodysplastic syndromes vol.6, pp.1, 2013, https://doi.org/10.3892/ol.2013.1346
  6. Analysis of the Paternally-Imprinted DLK1–MEG3 and IGF2–H19 Tandem Gene Loci in NT2 Embryonal Carcinoma Cells Identifies DLK1 as a Potential Therapeutic Target pp.1558-6804, 2018, https://doi.org/10.1007/s12015-018-9838-5
  7. Retinoic acid-dependent and -independent gene-regulatory pathways of Pitx3 in meso-diencephalic dopaminergic neurons vol.138, pp.23, 2010, https://doi.org/10.1242/dev.071704
  8. Cancer Stem Cells in Neuroblastoma: Expanding the Therapeutic Frontier vol.12, pp.None, 2010, https://doi.org/10.3389/fnmol.2019.00131